Skip to content
About
Management
Board of Directors
Scientific Advisory Board
Therapeutic Areas
Pipeline
OLX07010 in Rare Tauopathies
OLX07010 Alzheimer’s
Technology
MOA
Patents
News & Publications
Partners and Collaborators
Contact Us
Menu
Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company
Home
>
News
>
Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company
Print
Oligomerix
>
News
>
Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company
Oligomerix Announces Key Organizational Changes in Transition to Clinically Focused Company
Post navigation
Previous Post
Oligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development
Next Post
Oligomerix Awarded $3.35M from NIH to Support Clinical Development of Tau-Targeting Alzheimer’s Disease Therapy
vera
View posts by vera
Scroll to top
close ×
